RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability
CAMBRIDGE, Mass., Sept 14 (Bernama-BUSINESS WIRE) — RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, was part of a collaboration that recently shared new preclinical data at the IASLC 2023 World Conference on Lung Cancer in Singapore. The data, presented by Dr. Dean…

